Clinical trials: Type 2 Diabetes Risk
Type 2 Diabetes Mellitus, Hypertension
A Multi-site, Individually Randomized, Controlled Translation Trial of Integrated and Comprehensive Care Strategies to Reduce Cardiovascular Disease (CVD) Risk Among 1,120 Type 2 Diabetes Mellitus(T2DM) Patients in South Asia
Background: Cardiovascular diseases (CVD) are currently the leading cause of death globally and Asian Indians will account for between 40-60% of the global CVD burden within the next 10-15 years.
- Conditions
- Type 2 Diabetes Mellitus, Hypertension, Dyslipidaemia
- Trial name
- CARRS (NCT01212328)
- Testing
- Care Coordinator + Decision Support Software, Usual care
- Where
- 10 sites in India, Pakistan
- Volunteers
- 1,120 people
- Sponsor
- Public Health Foundation of India
Type 2 Diabetes
Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant
The investigators have recently discovered a genetic variant in an adrenergic receptor that leads to increased risk for type 2 diabetes.
- Trial name
- YOH1 (NCT01593215)
- Testing
- Yohimbine
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Anders Rosengren, MD PhD
Pre-Gestational Diabetes, Type2diabetes
Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching
The ACHIEVE RCT will measure the effect of the intervention (mHealth app with CGM, provider dashboard, and care team coaching) compared to current standard care (prenatal visits, self-monitored blood glucose, and certified…
- Conditions
- Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk
- Trial name
- NCT05662462
- Testing
- DEXCOM G7 PRO Continuous Glucose Monitor, Patient mHealth app linked to a provider dashboard, Care team coaching for medical and social needs (HUB)
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- Ohio State University
PreDiabetes
Effect of Egg Consumption on Cardiometabolic Health in Prediabetic Subjects.
The objective of this trial is to assess the effects of whole egg consumption (12 per week), compared to energy-matched typical breakfast control foods, on insulin sensitivity and other markers of metabolic health, including…
- Trial name
- NCT03332927
- Testing
- Egg based breakfast foods, Non-egg based breakfast foods
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Midwest Center for Metabolic and Cardiovascular Research
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Dietary Intervention to Improve Cardiometabolic Risk Profile in Individuals With Type 2 Diabetes
This is a randomized controlled trial to examine whether personalized guidance to increase the consumption of fiber rich food items according to the Dutch dietary guidelines, compared to usual care, improves health of individuals…
- Trial name
- VJBD2 (NCT05666843)
- Testing
- Personalized Dietary Advice
- Where
- Netherlands
- Volunteers
- 124 people
- Sponsor
- Wageningen University
Type 2 Diabetes, Cardiovascular Disease
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
The purpose of this study is to demonstrate no excess risk of cardiovascular (CV) composite events exists following long term treatment with TAK-875 compared with placebo.
- Trial name
- NCT01609582
- Testing
- TAK-875
- Where
- 584 sites in United States, Argentina and 30 more
- Volunteers
- 3,207 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2, Lifestyle Risk Reduction
Patient-Driven Lifestyle Modification Using FreeStyle Libre in Type 2 Diabetes Patients
We aim to provide medical nutritional therapy to patients with type 2 diabetes who are on oral hypoglycemic agents or on basal insulin only and monitor the glycemic response with flash glucose monitoring or self-monitoring of…
- Trial name
- PDF (NCT04932928)
- Testing
- FreeStyle Libre, Blood glucose meter
- Where
- South Korea
- Volunteers
- 126 people
- Sponsor
- Seoul National University Hospital
Psoriasis, Cardiovascular Diseases
The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis
Psoriasis vulgaris is no longer considered as a chronic inflammatory disease restricted to the skin. Evidence has accumulated in the past that psoriasis is a chronic inflammatory systemic disease.
- Conditions
- Psoriasis, Cardiovascular Diseases, Diabetes Mellitus, Type 2
- Trial name
- CASTIP (NCT01088165)
- Testing
- Adalimumab treatment arm, Fumaric acid esters treatment group, Narrow band UVB radiation
- Where
- Austria
- Volunteers
- 66 people
- Sponsor
- Medical University of Vienna
Type 2 Diabetes Mellitus, Obesity
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Overweight
- Trial name
- NCT07619495
- Testing
- Semaglutide, Dulaglutide
- Where
- United States
- Volunteers
- 120,000 people
- Sponsor
- Brigham and Women's Hospital
Type 2 Diabetes
Nationwide Assessment of Cardiovascular Risk Factors: in Chinese Patients With Type 2 Diabetes
The objective of this study is to evaluate the level of control of cardiovascular disease risk factors, including blood pressure, blood lipid, and blood glucose, in out patients with type 2 DM in 6 representative regions in…
- Trial name
- 3B (NCT01128205)
- Where
- China
- Volunteers
- 25,000 people
- Sponsor
- China Cardiometabolic Registries
Type 2 Diabetes Mellitus (T2DM)
The Effect of Individualized Nursing Interventions on Glycemic Variability and Self-Management in Type 2 Diabetes
Type 2 diabetes is a chronic disease with an increasing prevalence worldwide and in our country. In managing type 2 diabetes, the primary goal in the nursing process is to ensure blood glucose stability.
- Trial name
- NCT06973395
- Testing
- Nursing interventions, education, and follow-up will be provided to Type 2 diabetes patients for blood glucose variability.
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 72 people
- Sponsor
- Ataturk University
Bladder Cancer
Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy "PROBE"
Pioglitazone, an agonist of the peroxisome-proliferator-activated receptor (PPAR), is a relatively new oral anti-hyperglycemic drug.
- Trial name
- PROBE-PIO (NCT01935466)
- Testing
- Pioglitazone
- Where
- India
- Volunteers
- 6,107 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Diabetes Mellitus, Schizophrenia
Diabetes Prevention Program in Schizophrenia [DPPS]
Diabetes is 2-5 times more common in schizophrenia and it is a preventable; but the current diabetes prevention guidelines are not suitable for implementation in the severely mentally ill population.
- Trial name
- NCT00182494
- Testing
- Modified diabetes prevention protocol & Metformin
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Hamilton Health Sciences Corporation
Coronary Disease, Diabetes Mellitus, Non-Insulin-Dependent
Effects of Reiki on Painful Neuropathy and Cardiovascular Risk Factors
The object of this study is to determine if Reiki will improve glycemic control and cardiac autonomic function diabetic patients with painful neuropathy.
- Trial name
- NCT00010751
- Testing
- Reiki
- Where
- United States
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
PreDiabetes
Effect of the SCL16A11 Risk Haplotype on Treatments to Prevent Type 2 Diabetes
The goal of this randomized clinical trial is to determine the impact of the risk haplotype on SLC16A11 on early therapeutic responses in treatments to prevent T2D in Mexican mestizos with prediabetes.
- Trial name
- PRED2 (NCT05990205)
- Testing
- Life Style Intervention + Metformin, Life Style Intervention
- Where
- Mexico
- Volunteers
- 437 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Type2 Diabetes Mellitus
Adipose Tissue Expandability and Type 2 Diabetes
The goal of the study is to analyze deviations in adipogenic potential and metabolic properties of preadipocytes in subjects with genetic predisposition to type 2 diabetes, and thus identify factors that underlie hypertrophic…
- Trial name
- LIMEX (NCT03155412)
- Where
- Czechia
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Charles University, Czech Republic
PreDiabetes, Diabetes Mellitus
Diabetes Risk Education and Communication Trial
A large body of research has demonstrated that intensive lifestyle interventions and metformin are effective treatments to prevent or delay diabetes among high-risk adults, yet neither treatment is routinely used in practice.
- Conditions
- PreDiabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, Body Weight
- Trial name
- DiRECT (NCT03283657)
- Testing
- DiRECT, Usual care (UC)
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Pre-Diabetes
Genetic Physiopathology and Evolution of Type 2 Diabetes
There are few longitudinal studies in the Caucasian population and even less in the Italian population in subjects with impaired glucose regulation to allow: 1. An estimate of the rate of conversion to type 2 diabetes; 2.
- Trial name
- GENFIEV (NCT00879801)
- Where
- Italy
- Volunteers
- 1,017 people
- Sponsor
- University of Pisa
Diabetes Mellitus, Type 2
Empa PASS on Urinary Tract Malignancies
The aim of the study is to assess the risk of urinary tract malignancies in patients initiating empagliflozin (free or fixed dose combination) compared to patients initiating a dipeptidyl peptidase-4 (DPP-4) inhibitor.
- Trial name
- NCT03464045
- Testing
- empagliflozin, DPP-4 inhibitors
- Where
- 3 sites in Finland, Sweden and 1 more
- Volunteers
- 344,995 people
- Sponsor
- Boehringer Ingelheim
Diabetes
Preventing ESRD in Overt Nephropathy of Type 2 Diabetes
Nephropathy of type 2 diabetes is the leading cause of end stage renal disease (ESRD) world-wide and is associated with a dramatic excess cardiovascular morbidity and mortality.
- Trial name
- VALID (NCT00494715)
- Testing
- Benazepril, Valsartan, Benazepril/Valsartan
- Where
- 15 sites in Italy, Slovenia
- Volunteers
- 102 people
- Sponsor
- Mario Negri Institute for Pharmacological Research